Comparison of Immune Checkpoint Molecule Expression in Different Years of House Dust Mite Subcutaneous Immunotherapy on CD4 T and Treg Cells in Children with Allergic Rhinitis

Overview

Journal Balkan Med J

Publisher Galenos Publishing House

Specialty General Medicine

Date 2024 Sep 6

PMID 39239953

Authors

Zeynep Hizli Demirkale

Mehmet Fatih Alpkiray

Ayse Engin

Aybars Deniz Sonmez

Esra Yucel

Zeynep Tamay

Cevdet Ozdemir

Gunnur Deniz

Esin Cetin Aktas

Affiliations

Soon will be listed here.

Abstract

Background: Allergen-specific immunotherapy, a unique inducer of tolerance, may result in T cell exhaution.

Aims: To investigate how the duration of house dust mite (HDM) subcutaneous immunotherapy (SCIT) affects the expression of major immune checkpoint (ICP) molecules on the surface of CD4 T-helper and regulatory T (Treg) cells.

Study Design: Cross-sectional study.

Methods: We enrolled 28 children with HDM-induced allergic rhinitis (AR) and six controls. The study participants were divided into six groups: one group each of patients in their first, second, and third years of HDM-SCIT; one group each comprising those in the first year following HDM-SCIT and those on pharmacotherapy; and the control group. The expression of ICPs on CD4 T and Treg cells was determined using flow cytometry, and plasma levels of soluble ICPs were estimated by ELISA.

Results: Our results revealed a significant increase in the expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3) on CD4 T cells during the second and third years of SCIT, respectively. Additionally, a strong correlation was observed between the expression of CTLA-4 and T cell immunoglobulin and mucin domain containing molecule-3 in CD4 T cells. Furthermore, we observed a significant correlation between the expressions of programmed cell death protein-1, CTLA-4, T cell Immunoreceptor with Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif domain, and LAG-3 on both CD4 T and Treg cells. A robust correlation was observed between the plasma levels of soluble ICPs.

Conclusion: HDM-SCIT induces CD4 T cell exhaution, which may contribute to tolerance induction in children with AR.

References

Shokrgozar N, Karimi M, Golmoghaddam H, Rezaei N, Moayed V, Sharifzadeh S . Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype. Ann Hematol. 2021; 100(10):2463-2469. DOI: 10.1007/s00277-021-04605-w. View

Agache I, Lau S, Akdis C, Smolinska S, Bonini M, Cavkaytar O . EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019; 74(5):855-873. DOI: 10.1111/all.13749. View

Wambre E, DeLong J, James E, LaFond R, Robinson D, Kwok W . Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol. 2011; 129(2):544-51, 551.e1-7. PMC: 3268867. DOI: 10.1016/j.jaci.2011.08.034. View

Sauer N, Szlasa W, Jonderko L, Oslizlo M, Kunachowicz D, Kulbacka J . LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. Int J Mol Sci. 2022; 23(17). PMC: 9456311. DOI: 10.3390/ijms23179958. View

Wherry E, Kurachi M . Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8):486-99. PMC: 4889009. DOI: 10.1038/nri3862. View

Ozdemir C, Kucuksezer U, Akdis M, Akdis C . Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy. Immunol Allergy Clin North Am. 2015; 36(1):71-86. DOI: 10.1016/j.iac.2015.08.003. View

Li W, Syed F, Yu R, Yang J, Xia Y, Relich R . Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection. Front Immunol. 2022; 13:833310. PMC: 8904355. DOI: 10.3389/fimmu.2022.833310. View

Bacher P, Scheffold A . The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. J Allergy Clin Immunol. 2018; 142(6):1697-1709. DOI: 10.1016/j.jaci.2018.10.016. View

Noval Rivas M, Chatila T . Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016; 138(3):639-652. PMC: 5023156. DOI: 10.1016/j.jaci.2016.06.003. View

10.

Burton B, Britton G, Fang H, Verhagen J, Ben Smithers , Sabatos-Peyton C . Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014; 5:4741. PMC: 4167604. DOI: 10.1038/ncomms5741. View

11.

Okano M, Otsuki N, Azuma M, Fujiwara T, Kariya S, Sugata Y . Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis. Clin Exp Allergy. 2008; 38(12):1891-900. DOI: 10.1111/j.1365-2222.2008.03116.x. View

12.

Edner N, Carlesso G, Rush J, Walker L . Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020; 19(12):860-883. DOI: 10.1038/s41573-020-0081-9. View

13.

Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Togias A . Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160. DOI: 10.1111/j.1398-9995.2007.01620.x. View

14.

Mollavelioglu B, Aktas E, Cabioglu N, Abbasov A, Onder S, Emiroglu S . High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World J Surg Oncol. 2022; 20(1):349. PMC: 9587596. DOI: 10.1186/s12957-022-02810-z. View

15.

Wang S, Zissler U, Buettner M, Heine S, Heldner A, Kotz S . An exhausted phenotype of T 2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy. Allergy. 2021; 76(9):2827-2839. DOI: 10.1111/all.14896. View

16.

Engin A, Turna A, Esen F, Agkoc M, Cikman D, Saglam O . Mediastinal lymph node removal ameliorates cytotoxic T-lymphocyte functions in patients with non-small cell lung cancer. Tumori. 2021; 109(1):97-104. DOI: 10.1177/03008916211064643. View

17.

Khan M, Arooj S, Wang H . Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. Front Immunol. 2021; 12:651634. PMC: 8438243. DOI: 10.3389/fimmu.2021.651634. View

18.

Wang S, Chen C, Li M, Qian J, Sun F, Li Y . Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4T cells. Cell Death Dis. 2019; 10(1):15. PMC: 6325160. DOI: 10.1038/s41419-018-1251-0. View

19.

Rosskopf S, Jahn-Schmid B, Schmetterer K, Zlabinger G, Steinberger P . PD-1 has a unique capacity to inhibit allergen-specific human CD4 T cell responses. Sci Rep. 2018; 8(1):13543. PMC: 6131174. DOI: 10.1038/s41598-018-31757-z. View

20.

Aydogan M, Mete N, Yazi D, Akkoc T, Ozdemir C, Blaser K . Comparison of Der p1-specific antibody levels in children with allergic airway disease and healthy controls. Pediatr Allergy Immunol. 2007; 18(4):320-5. DOI: 10.1111/j.1399-3038.2007.00527.x. View